In a phase II basket trial, treatment with T-DM1 resulted in an ORR of 44.4%, meeting the primary study endpoint, and a median PFS of 5 months in heavily pretreated patients with HER2-mutant NSCLC [21]. Here, ERBB2 is linked to non-small cell lung carcinoma.